Chen X M, Kobayashi Y
Department of Internal Medicine, School of Medicine, Kitasato University, Kanagawa, Japan.
Nihon Jinzo Gakkai Shi. 1993 Mar;35(3):265-71.
Experiments were undertaken to study whether progressive processes of bovine serum albumin (BSA) nephritis in C57BL/B10-BR mice could be prevented by the treatment with methylprednisolone (MPSL), a glucocorticoid. Crescentic glomerulonephritis could be induced in 22 mice with high 95 per cent reproducibility by preimmunization of 0.2 mg of BSA four times every 2 weeks, followed by daily intraperitoneal injections of 50 mg/kg of BSA for 4 weeks (group IV, a control). In groups of 8 mice each, intraperitoneal injection of 50 mg/kg of MPSL was initiated 3 days before preimmunization (group I), before daily intraperitoneal injection of BSA (group II), and after daily intraperitoneal injection of BSA (group II), and after daily intraperitoneal injection of BSA (group III). In each group, the treatment was continued until the final day of the experiment. In group I, anti-BSA antibody titers, the levels of circulating immune complexes (CIC) and urinary protein was significantly suppressed in comparison with those in group IV. Histologically, diffuse intra- and extra-capillary proliferation observed in group IV was apparently inhibited. In group II and III, urinary protein and intra-/extracapillary proliferation were significantly diminished compared with those of group IV in spite of minor or no decrease in antibody titers and the CIC levels. These results suggest that MPSL has a suppressive effect on the progressive processes of immune complex mediated glomerulonephritis through both its immunosuppressive and antiinflammatory actions, especially when used in the early stage of immune reaction.
开展实验以研究糖皮质激素甲泼尼龙（MPSL）治疗是否可预防C57BL/B10 - BR小鼠中牛血清白蛋白（BSA）肾炎的进展过程。通过每2周4次预免疫0.2mg BSA，随后每天腹腔注射50mg/kg BSA，持续4周，可在22只小鼠中诱导出新月体性肾小球肾炎，重现性高达95%（IV组，作为对照）。在每组8只小鼠中，分别在预免疫前3天（I组）、每天腹腔注射BSA前（II组）以及每天腹腔注射BSA后（III组）开始腹腔注射50mg/kg MPSL。在每组中，治疗持续至实验最后一天。与IV组相比，I组中抗BSA抗体滴度、循环免疫复合物（CIC）水平和尿蛋白均显著受到抑制。组织学上，IV组中观察到的弥漫性毛细血管内和毛细血管外增殖明显受到抑制。在II组和III组中，尽管抗体滴度和CIC水平略有下降或未下降，但与IV组相比，尿蛋白和毛细血管内/外增殖显著减少。这些结果表明，MPSL通过其免疫抑制和抗炎作用，对免疫复合物介导的肾小球肾炎的进展过程具有抑制作用，尤其是在免疫反应早期使用时。
